In addition, phagocytosis of treated NSCLC cells and maturation (CD86) of DCs were significantly increased in all three human NSCLC cell lines after treatment with the above-mentioned chemotherapeutic regimens. The gene discussed is CD86; the disease is non-small cell lung carcinoma.